CoChat

Ceftazidime Monotherapy vs. Ceftriaxone/Tobramycin for Serious Hospital-Acquired Gram-Negative Infections

Rubinstein, E., Lode, H., Grassi, C., Antibiotic Study Group · 1995 · Clinical Infectious Diseases
Cited by 84

The DOI matches its Crossref record.

Abstract

We compared ceftazidime monotherapy with ceftriaxone/tobramycin in a prospective, randomized clinical trial that included 580 patients with serious hospital-acquired infections. One-half of the patients had an underlying disease with a rapidly or ultimately fatal prognosis; 40% were nursed in intensive care units. Clinical response among patients with pneumonia (73% in the ceftazidime group vs. 65% in the ceftriaxone/tobramycin group), septicemia (73% vs. 59%), and complicated urinary tract infections (80% vs. 76%) showed that there were no significant differences in efficacy between the two regimens. Pseudomonas aeruginosa was the most prevalent pathogen and was effectively eradicated by both treatments. The odds of bacteriologic cure with either study regimen were equal. Mortality was similar in both treatment groups. Ceftazidime monotherapy was not associated with a higher incidence of development of resistance or superinfection. Both regimens were well tolerated; no patients receiving ceftazidime evidenced nephrotoxicity, compared with nine who received the combination. We conclude that ceftazidime may be used as monotherapy in the empirical treatment of patients with serious nosocomial infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/clinids/20.5.1217

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 84

Metadata

Authors
Rubinstein, E., Lode, H., Grassi, C., & Antibiotic Study Group
Venue
Clinical Infectious Diseases
Published
1995-05-01
Volume
20
Issue
5
Pages
1217-1228
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W1982350853
Cited by
84
References
0
FWCI
2.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ceftazidime Monotherapy vs. Ceftriaxone/Tobramycin for Serious Hospital-Acquired Gram-Negative Infections. https://app.cochat.ai/papers/10.1093/clinids/20.5.1217
The paper
Rubinstein, E., Lode, H., Grassi, C., & Antibiotic Study Group. (1995). Ceftazidime Monotherapy vs. Ceftriaxone/Tobramycin for Serious Hospital-Acquired Gram-Negative Infections. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/20.5.1217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.